Search

Displaying results 1711 - 1720 of 2816 in total
  1. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Afri...

  2. Drug

    Risdiplam

    go.drugbank.com/drugs/DB15305
    ApprovedInvestigational

    Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism o...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  3. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist appro...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Danicopan

    go.drugbank.com/drugs/DB15401
    ApprovedInvestigational

    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction. Both hemolysis and thrombophilia are mediated primarily by the complement system. St...

    Categories: P-glycoprotein inhibitors
  5. Drug

    Yersinia pestis 195/p antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15461
    Investigational

    Yersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).

    Synonyms: Yersinia pestis 195/p antigen (formaldehyde inactivated)
  6. Drug

    Mexazolam

    go.drugbank.com/drugs/DB15489
    Investigational

    Mexazolam (CS-386) is a benzodiazepine indicated for the treatment of anxiety with or without psychoneurotic conditions. Mexazolam's structure is similar to that of other benzodiazepines such as oxazolam and cloxazolam. The use of benzod...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  7. Drug

    Sotorasib

    go.drugbank.com/drugs/DB15569
    ApprovedInvestigational

    Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  8. Drug

    Fennel

    go.drugbank.com/drugs/DB15615
    Approved

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2E1 Inhibitors
  9. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    SEP-363856 is a novel psychotropic drug being investigated for the treatment of schizophrenia. Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–assoc...

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Substrates
  10. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates